A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.
Among the 36 studies testing cagrilintide in Obesity, this one is the 10th largest by planned enrollment, is one of 6 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 13 of the 14 other live ones, and was the 21st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Greece, Hungary and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–64
Novo Nordisk A/S · Sites in Germany
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 154 across the 36 interventional studies. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 39th largest by planned enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2025, is one of 62 in phase 3, reaches primary completion later than 47 of the 65 other live ones, and was the 136th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
8 of the studies testing cagrilintide in Obesity that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07557953Novo Nordisk A/SA Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | 2027-04-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies testing cagrilintide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) after a dose escalation period of 16 weeks during the maintenance period for 88 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for one year.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously once weekly for 104 weeks. Participants randomised to this arm will be included in the extension phase for one year.
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Participants will receive cagrilintide subcutaneously.
Participants will receive semaglutide subcutaneously.
Participants will receive placebo matched to cagrilintide subcutaneously.
Participants will receive placebo matched to semaglutide subcutaneously.
Relative change in body weight
Measured in percentage (%).
Time frame: From baseline (week 0) to week 104
Number of participants who achieve greater than or equal to (>=) 20 percent body weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Number of participants who achieve >= 25 percent body weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Number of participants who achieve >= 30 percent body weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Change in waist circumference
Measured in centimeter (cm).
Time frame: From baseline (week 0) to week 104
Change in waist to height ratio
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Change in Systolic Blood Pressure (SBP)
Measured in millimeter of mercury (mmHg).
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: Total Cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: High Density Lipoprotein (HDL) Cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: Low Density Lipoprotein (LDL) Cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: Triglycerides
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: Free fatty acids
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Ratio to Baseline in Lipids: Non-HDL cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Change in Body Mass Index (BMI)
Measured in kilograms per meter square (kg/m\^2).
Time frame: From baseline (week 0) to week 104
Number of participants who achieve BMI less than 30 kg/m^2
Measured as count of participants.
Time frame: At week 104
Change in Glycated Haemoglobin (HbA1c) (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in HbA1c (millimoles per mole [mmol/mol])
Measured in mmol/mol.
Time frame: From baseline (week 0) to week 104
Change in Fasting Plasma Glucose (FPG) (millimoles per liter [mmol/L])
Measured as mmol/L.
Time frame: From baseline (week 0) to week 104
Change in FPG (milligrams per deciliter [mg/dL])
Measured as mg/dL.
Time frame: From baseline (week 0) to week 104
Number of participants who achieve HbA1c less than (<) 5.7 percent and FPG < 100 mg/dL with prediabetes at baseline
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Number of participants who achieve HbA1c >= 6.5 percent or FPG >= 126 mg/dL with prediabetes at baseline
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Time to HbA1c < 5.7 percent and FPG < 100 mg/dL with prediabetes at baseline
Measured in days.
Time frame: From baseline (week 0) to week 104
Time to HbA1c >= 6.5 percent or FPG >= 126 mg/dL with prediabetes at baseline
Measured in days.
Time frame: From baseline (week 0) to week 104
Number of participants who develop HbA1c >= 5.7 percent or FPG greater than (>) 100 mg/dL with normoglycemia at baseline
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Number of participants who develop type 2 diabetes (T2D) as per American Diabetes Association (ADA) guideline
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Time to T2D diagnosis as per ADA guideline
Measured in days.
Time frame: From baseline (week 0) to week 104
Change in American College of Cardiology/American Heart Association (ACC/AHA) 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score
Measured in percentage of risk. American College of Cardiology/American Heart Association (ACC/AHA) risk estimator calculates 10 year risk of atherosclerotic cardiovascular disease (ASCVD) using a formula which includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, smoking status; minimum score 0, maximum score 100 where higher score indicates higher risk of 10-year risk of atherosclerotic cardiovascular disease (ASCVD).
Time frame: From baseline (week 0) to week 104
Number of participants who improve in >= 1 pre-existing cardiometabolic obesity related com-plication (ORC) (hypertension, prediabetes, or dyslipidaemia)
Measured as count of participants.
Time frame: From baseline (week 0) to week 104
Ratio to baseline in C-reactive protein (CRP)
Measured as ratio.
Time frame: From baseline (week 0) to week 104
Change in total fat mass by dual energy X-ray absorption (DXA) absolute to total body mass (kilogram [kg])
Measured in kg.
Time frame: From baseline (week 0) to week 104
Change in total fat mass by DXA relative to total body mass (kg)
Measured in kg.
Time frame: From baseline (week 0) to week 104
Change in total fat mass by DXA absolute to total body mass (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in total fat mass by DXA relative to total body mass (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in visceral fat mass by DXA, relative to baseline in visceral fat mass region (percentage)
Measured in percentage.
Time frame: From baseline (week 0) to week 104
Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (percentage)
Measured in percentage.
Time frame: From baseline (week 0) to week 104
Change in visceral fat mass by DXA, relative to baseline in visceral fat mass region (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in lean body mass by DXA absolute to total body mass (kg)
Measured in kg.
Time frame: From baseline (week 0) to week 104
Change in lean body mass by DXA relative to total body mass (kg)
Measured in kg.
Time frame: From baseline (week 0) to week 104
Change in lean body mass by DXA absolute to total body mass (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in lean body mass by DXA relative to total body mass (percentage points)
Measured in percentage points.
Time frame: From baseline (week 0) to week 104
Change in Short Form (SF)-36 Physical functioning score
Measured as score points. The SF-36v2 acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. The scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical Functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.
Time frame: From baseline (week 0) to week 104
Change in Impact of Weight on Quality of Life-Lite for clinical trials (IWQOL-Lite-CT): Physical Function Score
Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.
Time frame: From baseline (week 0) to week 104
Change in IWQOL-Lite-CT: Physical Score
Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical score ranges from 0 to 100, with higher scores indicating better levels of functioning.
Time frame: From baseline (week 0) to week 104
Change in IWQOL-Lite-CT: Psychosocial score
Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Psychosocial score ranges from 0 to 100, with higher scores indicating better levels of functioning.
Time frame: From baseline (week 0) to week 104
Change in IWQOL-Lite-CT: Total score
Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Total score ranges from 0 to 100, with higher scores indicating better levels of functioning.
Time frame: From baseline (week 0) to week 104
Change in Impact of Weight on Daily Activities Questionnaire (IWDAQ) Composite score
Measured as score points. IWDAQ is an 18-item measure that uses an adaptive design to provide a personalised assessment of daily activity limitations associated with excess weight. At the baseline assessment the study participants choose the 3 activities (items) they would most like to improve the weight loss and rate the degree of limitation in each of these activities. At follow-up assessments, the study participants again rate the degree of current limitation in each of the same 3 activities. The measure yields the IWDAQ composite score with a score range from 3 to 15 with higher scores indicating greater personalised activity limitation.
Time frame: From baseline (week 0) to week 104
Change in Control of Eating questionnaire (CoEQ): Craving Control score
Measured as score points. CoEQ is a 19-item multidimensional patient reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.
Time frame: From baseline (week 0) to week 104
Change in CoEQ: Positive Mood score
Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the Positive Mood subscale, item 6 'How anxious have you felt?' is reversed.
Time frame: From baseline (week 0) to week 104
Change in CoEQ: Craving for Sweets score
Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving sweets food subscale, higher score represents a greater level of craving.
Time frame: From baseline (week 0) to week 104
Change in CoEQ: Craving for Savoury score
Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.
Time frame: From baseline (week 0) to week 104
Change in CoEQ: Hunger score
Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the hunger subscale, higher score represents a greater level of craving.
Time frame: From baseline (week 0) to week 104
Change in CoEQ: Satiety score
Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the satiety subscale, higher score represents a greater level of craving.
Time frame: From baseline (week 0) to week 104
CagriSema s.c. 2.4 mg/2.4 mg versus placebo: Number of Treatment Emergent Adverse Events (TEAEs)
Measured as count of events.
Time frame: From baseline (week 0) to week 104
CagriSema s.c. 2.4 mg/2.4 mg versus placebo: Number of Treatment Emergent Serious Adverse Events (TESAEs)
Measured as count of events.
Time frame: From baseline (week 0) to week 104
CagriSema s.c. 2.4 mg/2.4 mg versus CagriSema s.c. dose tapering algorithm: Number of TEAEs
Measured as count of events.
Time frame: From week 104 to end of study (week 162)
CagriSema s.c. 2.4 mg/2.4 mg versus CagriSema s.c. dose tapering algorithm: Number of TESAEs
Measured as count of events.
Time frame: From week 104 to end of study (week 162)
CagriSema 2.4 mg/2.4 mg: Number of TEAEs
Measured as count of events.
Time frame: From week 104 to end of study (week 162)
CagriSema 2.4 mg/2.4 mg: Number of TESAEs
Measured as count of events.
Time frame: From week 104 to end of study (week 162)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Aug 2028, 42 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 42 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide